Require around ₹3,000 crore to ramp up COVID-19 vaccine production: Adar Poonawalla

Serum Institute of India hopes to increase its capacity of Covishield to 110 million doses per month from June onwards

April 06, 2021 09:32 pm | Updated 09:32 pm IST - New Delhi

Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India. File

Adar Poonawalla, Chief Executive Officer (CEO) of the Serum Institute of India. File

Serum Institute of India (SII) would require around ₹3,000 crore to ramp up production capacity for making vaccines for COVID-19, its CEO Adar Poonawalla said on Tuesday.

"We need roughly ₹3,000 crores which is not a small figure considering we have already spent thousands of crores. We have to find other innovative ways to build our capacity so we can support our nation in light of COVID surge," Mr Poonawalla said in an interview to NDTV tweeted by the channel.

The company hopes to increase its capacity of Covishield to 110 million doses per month from June onwards, he added.

The company is producing 2 million doses per day, Mr Poonawalla said.

"We have delivered over 100 million doses to India alone and exported around 60 million doses to other countries," he added.

Serum Institute along with other vaccine producers have agreed with the government to sacrifice profits. There is no vaccine industry on the planet that has agreed to provide vaccines at such a subsidised price, he added.

In another interview to ET NOW, Mr Poonawalla said that Serum Institute is prioritising temporarily needs of India before others.

The company currently has capacity to produce 60 to 70 million doses per month, he said.

The vaccine industry has sacrificed millions of dollars to support the nation, he added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.